Intra-population differences of apolipoproteins in the aqueous humor.
Journal
Lipids in health and disease
ISSN: 1476-511X
Titre abrégé: Lipids Health Dis
Pays: England
ID NLM: 101147696
Informations de publication
Date de publication:
03 Oct 2021
03 Oct 2021
Historique:
received:
21
07
2021
accepted:
13
09
2021
entrez:
4
10
2021
pubmed:
5
10
2021
medline:
8
2
2022
Statut:
epublish
Résumé
Evidence suggests that proteins related to lipid metabolism, such as apolipoproteins, play an important role in the maintenance of normal vision. While several members of the apolipoprotein family are abundant in human aqueous humor (AH), their study remains difficult due to the AH's small volume, low protein concentration, and the invasive nature of sample collection. In this study, we report the use of Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS) to discover associations between AH apolipoproteins and race, gender, and ocular structure in patients with and without primary open angle glaucoma (POAG). AH samples were collected from 231 patients undergoing phacoemulsification or glaucoma incisional surgery at the Medical College of Georgia, Augusta University and subsequently analyzed via LC-MS/MS. The number of peptide spectrum matches (PSMs) for each protein was used as a semi-quantitative measure of relative protein levels. Parameters related to ocular structure were determined using Optical Coherence Tomography (OCT) and Heidelberg Retinal Tomography (HRT). These data sets were probed for relationships between apolipoprotein levels and POAG, demographics (gender and race), and ocular structure. A total of ten apolipoproteins were detected in the 231 collected AH samples, with six detected in 100% of the samples, one detected in almost 57% of the samples and three detected in less than 10% of the samples. The levels of APOA1, APOC3, and APOD were higher among POAG subjects. Stratification by gender and race revealed demographic-specific variations. The levels of five apolipoproteins (APOA1, APOA2, APOA4, APOC3, and APOD) were higher in female POAG patients, whereas no apolipoprotein levels were altered in male POAG patients. The levels of APOA1, APOA2, APOA4, and APOD were increased in glaucomatous African American patients, whereas APOE and APOH levels were decreased in glaucomatous Caucasian patients. We also found distinct associations between apolipoprotein levels and OCT and HRT parameters in patients with and without POAG. The intra-population variation in apolipoprotein levels highlights the heterogeneity of glaucoma as a disease, suggesting the importance of personalized treatments. Gender and race-specific alterations may be associated with higher risks of POAG in females and members of the African American population.
Sections du résumé
BACKGROUND
BACKGROUND
Evidence suggests that proteins related to lipid metabolism, such as apolipoproteins, play an important role in the maintenance of normal vision. While several members of the apolipoprotein family are abundant in human aqueous humor (AH), their study remains difficult due to the AH's small volume, low protein concentration, and the invasive nature of sample collection. In this study, we report the use of Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS) to discover associations between AH apolipoproteins and race, gender, and ocular structure in patients with and without primary open angle glaucoma (POAG).
METHODS
METHODS
AH samples were collected from 231 patients undergoing phacoemulsification or glaucoma incisional surgery at the Medical College of Georgia, Augusta University and subsequently analyzed via LC-MS/MS. The number of peptide spectrum matches (PSMs) for each protein was used as a semi-quantitative measure of relative protein levels. Parameters related to ocular structure were determined using Optical Coherence Tomography (OCT) and Heidelberg Retinal Tomography (HRT). These data sets were probed for relationships between apolipoprotein levels and POAG, demographics (gender and race), and ocular structure.
RESULTS
RESULTS
A total of ten apolipoproteins were detected in the 231 collected AH samples, with six detected in 100% of the samples, one detected in almost 57% of the samples and three detected in less than 10% of the samples. The levels of APOA1, APOC3, and APOD were higher among POAG subjects. Stratification by gender and race revealed demographic-specific variations. The levels of five apolipoproteins (APOA1, APOA2, APOA4, APOC3, and APOD) were higher in female POAG patients, whereas no apolipoprotein levels were altered in male POAG patients. The levels of APOA1, APOA2, APOA4, and APOD were increased in glaucomatous African American patients, whereas APOE and APOH levels were decreased in glaucomatous Caucasian patients. We also found distinct associations between apolipoprotein levels and OCT and HRT parameters in patients with and without POAG.
CONCLUSIONS
CONCLUSIONS
The intra-population variation in apolipoprotein levels highlights the heterogeneity of glaucoma as a disease, suggesting the importance of personalized treatments. Gender and race-specific alterations may be associated with higher risks of POAG in females and members of the African American population.
Identifiants
pubmed: 34602085
doi: 10.1186/s12944-021-01555-0
pii: 10.1186/s12944-021-01555-0
pmc: PMC8487476
doi:
Substances chimiques
Apolipoproteins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
128Subventions
Organisme : NEI NIH HHS
ID : P30 EY031631
Pays : United States
Organisme : NEI NIH HHS
ID : R01 EY029728
Pays : United States
Organisme : NEI NIH HHS
ID : R01-EY029728
Pays : United States
Informations de copyright
© 2021. The Author(s).
Références
Proteomics. 2016 Jul;16(13):1938-46
pubmed: 27193151
Exp Eye Res. 2011 Jan;92(1):67-75
pubmed: 21078314
Curr Org Chem. 2013 Dec;17(23):2891-2905
pubmed: 24376367
J Neurochem. 1998 Oct;71(4):1643-50
pubmed: 9751198
J Cereb Blood Flow Metab. 2008 Mar;28(3):551-62
pubmed: 17851453
Clin Chem Lab Med. 2014 Dec;52(12):1695-727
pubmed: 23940067
Curr Eye Res. 2015 Feb;40(2):191-200
pubmed: 25285808
Br J Ophthalmol. 2010 Jul;94(7):827-30
pubmed: 20606021
Neuron. 2009 Aug 13;63(3):287-303
pubmed: 19679070
Invest Ophthalmol Vis Sci. 2020 Dec 1;61(14):6
pubmed: 33270842
Invest Ophthalmol Vis Sci. 2018 May 1;59(6):2635-2643
pubmed: 29847670
Arch Ophthalmol. 2008 Aug;126(8):1076-81
pubmed: 18695102
Surv Ophthalmol. 2021 Sep-Oct;66(5):693-713
pubmed: 33582161
J Glaucoma. 2017 Apr;26(4):349-355
pubmed: 28221327
Mol Pharm. 2013 Aug 5;10(8):3253-61
pubmed: 23841874
J Clin Med. 2021 Mar 12;10(6):
pubmed: 33808966
OMICS. 2015 May;19(5):283-93
pubmed: 25933257
BMC Ophthalmol. 2012 Sep 18;12:50
pubmed: 22988958
J Lipid Res. 1982 Aug;23(6):850-62
pubmed: 6813411
Mol Cell Proteomics. 2021 Jun 30;20:100117
pubmed: 34214668
Invest Ophthalmol Vis Sci. 2005 Oct;46(10):3742-52
pubmed: 16186358
Mol Neurodegener. 2020 Jan 31;15(1):8
pubmed: 32005122
Dev Neurobiol. 2007 Apr;67(5):603-16
pubmed: 17443811
Curr Mol Med. 2003 Aug;3(5):408-18
pubmed: 12942994
Biology (Basel). 2021 Jul 13;10(7):
pubmed: 34356513
Invest Ophthalmol Vis Sci. 2012 Jun 28;53(7):4242-53
pubmed: 22618596
Medicine (Baltimore). 2017 Jan;96(1):e5834
pubmed: 28072742
Clin Chem. 2009 Mar;55(3):407-19
pubmed: 19168552
Atherosclerosis. 2000 Aug;151(2):381-8
pubmed: 10924714
Invest Ophthalmol Vis Sci. 1999 Aug;40(9):1989-97
pubmed: 10440253
PLoS One. 2012;7(1):e29937
pubmed: 22253831
PLoS One. 2017 Mar 8;12(3):e0172481
pubmed: 28273097
J Neurosci. 1994 Jan;14(1):357-67
pubmed: 8283243
Proteomics Clin Appl. 2007 Aug;1(8):876-88
pubmed: 21136741
Invest Ophthalmol Vis Sci. 2008 Jan;49(1):66-76
pubmed: 18172076
Mol Med Rep. 2017 May;15(5):3111-3120
pubmed: 28339073
Ann Clin Biochem. 2011 Nov;48(Pt 6):498-515
pubmed: 22028427
Sci Rep. 2021 Jul 2;11(1):13762
pubmed: 34215769
Arch Ophthalmol. 2004 Apr;122(4):532-8
pubmed: 15078671
Invest Ophthalmol Vis Sci. 2013 Aug 09;54(8):5353-8
pubmed: 23860758
Exp Eye Res. 2005 Aug;81(2):176-82
pubmed: 16080911
J Neuroimmunol. 2001 Oct 1;119(2):327-32
pubmed: 11585636
Mol Cell Proteomics. 2004 Jan;3(1):1-9
pubmed: 14608001
Clin Endocrinol (Oxf). 2016 Nov;85(5):733-740
pubmed: 27086565
Mol Neurodegener. 2019 Jun 11;14(1):24
pubmed: 31186040
Acta Ophthalmol Scand. 2005 Aug;83(4):409-18
pubmed: 16029262
Proteomes. 2020 Nov 18;8(4):
pubmed: 33217969
Neuropsychiatr Dis Treat. 2015 Jul 16;11:1723-37
pubmed: 26213471
BMC Ophthalmol. 2016 May 01;16(1):47
pubmed: 27138378
Mol Neurobiol. 2002 Oct-Dec;26(2-3):369-88
pubmed: 12428765
Circulation. 2011 Nov 8;124(19):2065-72
pubmed: 21986282
Invest Ophthalmol Vis Sci. 2010 Oct;51(10):4921-31
pubmed: 20463327
Clin Biochem. 2015 Dec;48(18):1304-9
pubmed: 26265347
BMC Ophthalmol. 2018 Nov 7;18(1):289
pubmed: 30404605
Ann Clin Biochem. 2002 Jan;39(Pt 1):56-61
pubmed: 11853190
J Neurochem. 1995 Oct;65(4):1752-9
pubmed: 7561873
PLoS One. 2016 Oct 27;11(10):e0165314
pubmed: 27788204
Neurosurg Focus. 2015 Nov;39(5):E3
pubmed: 26646927